Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CEMI Chembio Diagnostics	$0.46	$0.43	$0.19 ▼ $1.24	$16.71M	1.85	661,416 shs	351,642 shs
CMPX Compass Therapeutics	$2.58 -0.8%	$2.17	$0.77 ▼ $4.08	$356.76M	1.42	963,765 shs	611,592 shs
ENLV Enlivex Therapeutics	$1.12	$1.01	$0.81 ▼ $1.76	$26.49M	0.74	128,803 shs	54,537 shs
ORGS Orgenesis	$1.53 +3.7%	$2.00	$0.87 ▼ $10.80	$7.34M	0.54	8,434 shs	5,455 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CEMI Chembio Diagnostics	0.00%	0.00%	0.00%	0.00%	0.00%
CMPX Compass Therapeutics	+1.56%	+2.36%	+21.50%	+16.07%	+160.00%
ENLV Enlivex Therapeutics	-6.67%	-3.45%	+16.25%	+17.89%	-21.13%
ORGS Orgenesis	-1.67%	-15.42%	-23.97%	-38.80%	+147,499,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	3.7594 of 5 stars	4.6	2.0	0.0	0.0	2.1	5.0	0.0
ENLV Enlivex Therapeutics	3.3083 of 5 stars	3.7	5.0	0.0	0.0	2.7	0.8	0.6
ORGS Orgenesis	1.8229 of 5 stars	0.0	5.0	0.0	4.4	0.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CEMI Chembio Diagnostics	0.00	N/A	N/A	N/A
CMPX Compass Therapeutics	3.10	Buy	$12.67	390.96% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	792.86% Upside
ORGS Orgenesis	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ORGS, ENLV, CEMI, and CMPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/21/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/21/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/4/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $24.00
4/3/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/2/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/2/2025	CMPX Compass Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $6.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CEMI Chembio Diagnostics	$48.34M	0.35	N/A	N/A	$0.48 per share	0.95
CMPX Compass Therapeutics	$850K	419.72	N/A	N/A	$0.91 per share	2.84
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
ORGS Orgenesis	$662K	11.09	N/A	N/A	($6.58) per share	-0.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CEMI Chembio Diagnostics	-$23.29M	-$1.20	N/A	∞	N/A	-47.03%	-113.57%	-38.22%	N/A
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
ORGS Orgenesis	-$55.36M	N/A	0.00	∞	N/A	-3,827.81%	N/A	-130.18%	8/6/2025 (Estimated)

Latest ORGS, ENLV, CEMI, and CMPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CEMI Chembio Diagnostics	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
ORGS Orgenesis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CEMI Chembio Diagnostics	N/A	1.23	1.04
CMPX Compass Therapeutics	N/A	8.33	8.33
ENLV Enlivex Therapeutics	N/A	7.20	7.20
ORGS Orgenesis	N/A	0.07	0.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CEMI Chembio Diagnostics	8.65%
CMPX Compass Therapeutics	68.43%
ENLV Enlivex Therapeutics	1.02%
ORGS Orgenesis	22.56%

Insider Ownership

Company	Insider Ownership
CEMI Chembio Diagnostics	3.30%
CMPX Compass Therapeutics	29.80%
ENLV Enlivex Therapeutics	12.28%
ORGS Orgenesis	5.66%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CEMI Chembio Diagnostics	337	36.73 million	35.51 million	Not Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
ORGS Orgenesis	150	4.80 million	4.53 million	No Data

ORGS, ENLV, CEMI, and CMPX Headlines

Recent News About These Companies

Orgenesis Delays Filing of Quarterly Report

May 16, 2025 | tipranks.com

Orgenesis Delays 10-K Filing Amid Financial Challenges

April 1, 2025 | tipranks.com

Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies

March 6, 2025 | accessnewswire.comA

Orgenesis Inc. (ORGS) Stock Price, News, Quote & History - Yahoo Finance

February 9, 2025 | finance.yahoo.com

Orgenesis secures $5M equity investment from Williamsburg Venture

January 29, 2025 | markets.businessinsider.com

Orgenesis Inc: Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings

January 28, 2025 | finanznachrichten.de

Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings

January 28, 2025 | accessnewswire.comA

Orgenesis Inc. Reports Q3 2024 Financial Results

November 15, 2024 | markets.businessinsider.com

Orgenesis Provides Third Quarter 2024 Business Update

November 13, 2024 | markets.businessinsider.com

Orgenesis Expands Board with Three New Appointments

November 3, 2024 | markets.businessinsider.com

Orgenesis commences trading on OTCQX Best Market

October 22, 2024 | markets.businessinsider.com

Orgenesis Commences Trading on OTCQX® Best Market

October 21, 2024 | markets.businessinsider.com

Orgenesis (NASDAQ:ORGS) Stock Quotes, Forecast and News Summary

October 4, 2024 | benzinga.com

45O.SG,0P0001J8IU,0 (45O.SG)

September 24, 2024 | au.finance.yahoo.com

Why Orgenesis (ORGS) Stock Is Down 23% Today

September 24, 2024 | msn.com

Orgenesis Inc.: Orgenesis Announces Reverse Stock Split

September 23, 2024 | finanznachrichten.de

Orgenesis Approves 1-for-10 Reverse Stock Split

September 23, 2024 | markets.businessinsider.com

Orgenesis Announces Reverse Stock Split

September 23, 2024 | markets.businessinsider.com

Is Orgenesis Stock (ORGS) a Good Investment?

September 19, 2024 | aaii.comA

Orgenesis Advancing CD19 CAR T-cell Therapy Into Phase I/II Leukemia Trial

August 31, 2024 | precisionmedicineonline.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGS, ENLV, CEMI, and CMPX Company Descriptions

Chembio Diagnostics NASDAQ:CEMI

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Compass Therapeutics NASDAQ:CMPX

$2.58 -0.02 (-0.77%)

Closing price 04:00 PM Eastern

Extended Trading

$2.60 +0.02 (+0.74%)

As of 05:51 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Enlivex Therapeutics NASDAQ:ENLV

$1.12 0.00 (0.00%)

As of 04:00 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Orgenesis NASDAQ:ORGS

$1.53 +0.06 (+3.73%)

As of 03:39 PM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time